Traduction de «january 2007 there has been » (Néerlandais → Français) :

In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.
In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.

There has been no tradition of systematically gathering and tracking patient feedback over time – let alone using the findings to continually review and improve se [ bibliotheek ] [ 25/09/2012 ]
There has been no tradition of systematically gathering and tracking patient feedback over time – let alone using the findings to continually review and improve se [ Bibliothèque ] [ 25/09/2012 ]

Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.
Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.

On 1 January 2007, the FAMHP took over 325 Dutch-language applications that had not yet been finalised on the basis of the establishment regulations (royal decree of 25 September 1974 on the opening, transfer and merger of retail pharmacies).
On 1 January 2007, the FAMHP took over 325 Dutch-language applications that had not yet been finalised on the basis of the establishment regulations (royal decree of 25 September 1974 on the opening, transfer and merger of retail pharmacies).

Rasilez HCT, a single-pill combination with a diuretic, has been launched in Europe after approval in January 2009.
Rasilez HCT, un comprimé l’associant à un diurétique, est maintenant commercialisé en Europe après l’autorisation délivrée en janvier 2009.

Exforge received regulatory approval in Japan in January 2010, while Exforge HCT, which adds a diuretic in a single pill, has been a key growth driver in both the US and Europe.
Exforge a reçu en janvier 2010 une autorisation de mise sur le marché au Japon, tandis qu’Exforge HCT, qui y ajoute un diurétique en un seul comprimé, a été un moteur-clé de la croissance tant aux Etats-Unis qu’en Europe.

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.
For 2007, an analysis has been performed of the number of submitted applications versus the number of MA of medicines for human use granted.

At present there are five agents who belong to the internal FAMHP team and ten agents who are supplied by the ICT service of the FPS Public Health, with which an SLA has been concluded in order to bring to a successful conclusion the transfer of tools and IT skills from the former DG Medicinal Products to the FAMHP and ensure the continuity of service provision.
At present there are five agents who belong to the internal FAMHP team and ten agents who are supplied by the ICT service of the FPS Public Health, with which an SLA has been concluded in order to bring to a successful conclusion the transfer of tools and IT skills from the former DG Medicinal Products to the FAMHP and ensure the continuity of service provision.

The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.
The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.